5 Key Takeaways
-
1
Avisi Technologies presented two-year follow-up data from its VITA trial of the investigational VisiPlate aqueous shunt at the 2026 AAO Annual Meeting.
-
2
VITA is a prospective, single-arm, multicenter, open-label trial evaluating VisiPlate in patients with primary open-angle glaucoma.
-
3
The study was conducted at three sites in South Africa, and the latest analysis extended follow-up to two years.
-
4
VisiPlate is an ultrathin, multichannel shunt designed to drain aqueous humor from the anterior chamber while reducing the risk of obstruction.
-
5
Avisi is continuing to evaluate VisiPlate in its US clinical development program.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
